Empagliflozin benefits adults hospitalised for acute heart failure, shows study
Phase III trial shows that adults hospitalised for acute heart…
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.